Lead Product(s): EB005
Therapeutic Area: Dermatology Product Name: EB005
Highest Development Status: Discovery Product Type: Undisclosed
Deal Size: $224.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2021
Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in acne.